TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Cancer Screening Program for Women at High Risk for Developing Ovarian Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must meet one of the following:~  * The family contains at least two ovarian or breast cancers in the subject or first or second degree relatives of the subject.~ * The subject is of Ashkenazi Jewish ethnicity with one first degree or two second-degree relatives with breast or ovarian cancer, or subject is of Ashkenazi ancestry and has had breast cancer.~ * The subject has a male relative with breast cancer diagnosed at any age.~ * Probability of carrying a BRCA1/2 mutation given family pedigree of breast and ovarian cancers exceeds 20% (as determined by BRCAPRO 95% posterior probability interval).~Exclusion Criteria:~* Prior ovarian cancer or peritoneal carcinomatosis~* A first or second degree relative with a BRCA1/2 mutation and has tested negative for exactly the same mutation.~* The subject has no ovaries.~* Less than 30 years of age, unless 25-30 with BRCA I or II mutation confirmed~* Currently pregnant~* Currently receiving adjuvant chemotherapy or radiation therapy for cancer (excluding tamoxifen). Patients who are being treated for local disease may enroll 3 months after completion of last treatment (excluding tamoxifen).~* Treatment (excluding tamoxifen) for prior metastatic malignancy within the past five years.~* Intraperitoneal surgery within the last 3 months.

- Gender: FEMALE
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Ovarian Cancer Screening (Type: EXPERIMENTAL): CA125 tumor marker, Transvaginal Ultrasound, Health Status Questionnaires

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Intranasal Administration of Niclosamide (UNI91103) in Adults With Asymptomatic or Mild COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is male or female aged ≥45 and \<80 years~* Subject is tested to confirm infection with SARS-CoV-2 on a sample taken within 3 days before randomization~* Subject is either without symptoms or has 1 or more of the following symptoms: Stuffy or runny nose, Sore throat, Loss of taste, Loss of smell, Headache.~None of the symptoms should have been present \>5 days.~Exclusion Criteria:~* Subject has an underlying condition that may interfere with intranasal administration of the IMP (e.g., chronic ulcers in the nose).~* Subject has symptoms suggesting engagement of the lower respiratory tract or a systemic engagement~* Subject has an active or acute infection other than SARS-CoV-2~* Subject has another member of the same household recruited to this study

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- UNI91103 intranasal spray 1% (Type: EXPERIMENTAL): UNI91103 intranasal spray 1%, BID, 10 consecutive days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo intranasal spray, BID, 10 consecutive days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Long Term Survivors in Ovarian Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~To achieve a large enough study population of approximately 80 subjects, patients surviving \>10 years after treatment for stage IIIC/IV epithelial ovarian cancer in the past 25 years will be included from five hospitals. Patients were diagnosed between 1979 and 2006 and treated in the north of the Netherlands. A list of subjects fitting these inclusion criteria will be extracted from the National Cancer Registry (NKR).

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- long-term survivors of ovarian cancer (Type: None): long-term survivors of ovarian cancer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Implantable Cardioverter-Defibrillator (ICD) Implantation in the Elderly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 70 years of age or older~2. Eligible for ICD implementation according to the CMS criteria for primary prevention by one of the following conditions:~   1. Documented prior MI and a measured left ventricular ejection fraction (LVEF) \<=30% (includes New York Heart Association \[NYHA\] class I, II, or III)~  2. Coronary artery disease with a documented prior MI, a measured left ventricular ejection fraction \<=35%, and inducible, sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) at electrophysiology (EP) study~  3. Ischemic dilated cardiomyopathy (IDCM), documented prior MI, NYHA class II and III heart failure, and measured LVEF \<=35%~  4. Non-ischemic dilated cardiomyopathy (NIDCM) \> 3 months, NYHA Class II and III heart failure, and measured LVEF \<=35%~3. Stable condition on Optimal Medical Therapy~4. Able and willing to provide informed consent to participate in this study~Exclusion Criteria:~1. Enrolled in or planning to enroll in a conflicting trial~2. Receiving a bi-ventricular ICD device~3. New York Heart Association class IV heart failure~4. Cardiogenic shock or symptomatic hypotension while in stable baseline rhythm,~5. Coronary artery bypass graft (CABG) or percutaneous transluminal coronary angioplasty (PTCA) within the past 3 months~6. An MI within the past 40 days~7. Clinical symptoms or findings that would make them a candidate for coronary revascularization~8. Irreversible brain damage from pre-existing cerebral disease~9. Any disease other than cardiac disease (e.g. cancer, uremia, liver failure), associated with a likelihood of survival less than 1 year~10. Circumstance that would prevent completion of the trial and follow-up activities, including medical condition

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): ICD implantation in addition to Optimal Medical Therapy
- 2 (Type: ACTIVE_COMPARATOR): Optimal Medical Therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: The p53 Colorectal Cancer Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Metastatic colorectal cancer patients for whom conventional therapy has failed; defined as 2 lines of chemotherapy including oxaliplatin or irinotecan- containing regimens as well as an EGFR inhibitor if applicable.~* Tumor lesion suitable for biopsy~* Age \>18 years~* Clinically or radiologically measurable tumor deposits according to the RECIST criteria~* WHO performance status 0-1~* Radiology studies (CT thorax/abdomen/pelvis) and echo cor and ECG must be performed within 28 days prior to registration.~* Before patient registration in the trial, written informed consent must be given according to national and local regulations.~* Blood test requirements:~Neutrophils \> 1.0 e9/L Platelets \> 75 e9/L Bilirubin \< 20 µmol / L. Serum creatinine \< 1.5 x ULN~Exclusion Criteria:~* Co-morbidity including, but not limited to, impaired renal-, liver or bone marrow function, that based on the assessment of the treating physician, may preclude the use of cyclophosphamide at actual doses.~* Known hypersensitivity to the study drug, its metabolites or any excipients in the infusion solution.~* Psychological, familial, sociological or geographical condition(s) potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial~* Pregnant or lactating patients cannot be included.~* Clinical evidence of serious coagulopathy. Prior arterial/venous thrombosis or embolism does not exclude patients from inclusion, unless patient is considered unfit by study oncologist.~* Patient not able to give an informed consent or comply with study regulations as deemed by study investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cyclophosphamide arm (Type: EXPERIMENTAL): Dose dense cyclophosphamide (1800 Mg/m2) administered intravenously every second week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study To Assess Guidance in and Subsequent Use of Mind-Body Techniques on the Quality of Life of Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* TNM staged tumors Stage I to Stage IV,~* Tumors staged according to the Ann Arbor staging classification system (commonly lymphomas)~* Tumors which don't have a clear-cut staging system such as most types of leukemia and blood or bone marrow cancers~* Tumors staged by the International Federation of Gynecology and Obstetrics (cervix, uterus, ovary, vagina, and vulva).~* No neurological illness~Exclusion Criteria:~* Mental functioning clinically estimated to be below the low average range (IQ\< 80). (Impaired cognitive level might impede verbal comprehension).~* Not being able to speak or understand English;~* No access to reliable computer with operational software to participate in online video conferences~* Unavailability of built-in or external web-cam~* Unavailability of reliable high-speed Internet connection~* Unavailability of reliable transportation to and from face-to-face MBM skills group meetings~* Barring unforeseen circumstances, intent to participate in each and every one of the eight MBM Skills Groups session

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Face-to-Face MBM Skills Group (Type: EXPERIMENTAL): None
- Online MBM Skills Group (Type: EXPERIMENTAL): None
- Waitlist Control I (Type: OTHER): This group will be given the option to participate in a face-to-face MBM skills group intervention after conclusion of study.
- Waitlisted Control II (Type: OTHER): This group will be given the option to participate in an Online MBM skills group intervention after conclusion of study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Admitted for delivery~* Pre-pregnancy BMI \> 30kg/m2~* Planned vaginal delivery at Geisinger Medical Center (GMC)~* Gestational age \> 37 weeks 0 days~* Singleton pregnancy~* Cephalic presentation~* English speaking~Exclusion Criteria:~* Pre-pregnancy BMI \< 30kg/m2~* Contraindication to vaginal delivery~* Planned cesarean delivery (i.e., an elective primary or repeat cesarean delivery)~* Gestational age \< 37 weeks 0 days~* Multifetal gestation~* Intrauterine fetal demise~* Non-English speaking~* Greater than 9cm at the time of randomization

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Peanut Ball Arm (Type: EXPERIMENTAL): Study participants randomized to the Peanut Ball Arm will have the peanut ball placed during labor. Study participants will be required to use the peanut ball for a minimum of 30 minutes of each hour until they reach complete dilation. Peanut ball use time will be noted in the patient's chart.
- Control Arm (Type: NO_INTERVENTION): Study participants randomized to the Control Arm will labor without the peanut ball.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate the Safety, Local Tolerability, PK and PD of LDE225 on Sporadic Superficial and Nodular Skin Basal Cell Carcinomas (sBCC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with one histologically confirmed superficial and nodular basal cell carcinoma (8-20 mm) eligible for surgical excision on selected body areas (scalp, arm, frontal trunk, posterior trunk, upper legs)~Exclusion Criteria:~* Previous treatment of the sBCC that are selected for treatment.~* Any systemic treatment which is known to affect BCCs esp. cytostatic treatments, retinoids and photodynamic treatments.~* Dark-skinned persons whose skin color prevents readily assessment of skin reactions~Other protocol defined Incl./Excl. criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- LDE225 0.75% (Type: EXPERIMENTAL): Participants topically applied 0.75% LDE225 cream twice daily for 6 weeks.
- Vehicle (Type: PLACEBO_COMPARATOR): Participants topically applied matching placebo cream twice daily for 6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Outcome in View of Surgical Site Infection (SSI) With Antibacterial Skin Sutures

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All patients from the Visceral Department of Basel University Hospital requiring open abdominal surgery. Open abdominal surgery is defined as: opened peritoneal cavity~Exclusion Criteria:~* factors limiting the ability to co-operate in the study;~* absence of signed informed consent before entering the study;~* people with mental disorders;~* pregnant women;~* participants under 18 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort one with abdominal wall closure with Monocryl (Type: None): None
- Cohort two with abdominal wall closure with Monocryl plus (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Thalidomide for the Treatment of Primary Sclerosing Cholangitis (PSC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Previous diagnosis of primary sclerosing cholangitis as defined by: serum alkaline phosphatase level greater than or equal to 1.5 times the upper limit of normal, negative serum antimitochondrial antibody test, cholangiography diagnostic of PSC without other etiology for biliary obstruction, and liver histology consistent with or diagnostic of PSC~* Patients must give written informed consent.~* Patients must be willing and able to comply with the most recent version of the FDA-mandated System for Thalidomide Education and Prescribing Safety (S.T.E.P.S.®) program.~Exclusion Criteria:~* Pregnant and/or lactating female~* Inability or unwillingness to practice contraceptive measures for the prevention of pregnancy~* History of hypersensitivity reaction to thalidomide~* Inability to provide consent~* Findings suggestive of liver disease of other etiology such as primary biliary cirrhosis, chronic alcoholic liver disease, chronic hepatitis B and C infection, hemochromatosis, Wilson's disease, alpha-1-antitrypsin deficiency, autoimmune hepatitis, and cryptogenic liver disease~* Anticipated need for liver transplantation in one year from decompensated chronic liver disease or recurrent variceal bleeding, spontaneous hepatic encephalopathy, or refractory ascites~* Treatment with tacrolimus, cyclosporine, sirolimus, ursodeoxycholic acid, corticosteroids, colchicine, methotrexate, azathioprine, cyclosporine, chlorambucil, budesonide, pentoxifylline, nicotine, silymarin, vitamin E or pirfenidone in the preceding three months~* History of peripheral neuropathy~* Use of medications with significant drug-drug interactions with thalidomide~* History of Human Immunodeficiency Virus (HIV) positive status or Acquired Immunodeficiency Syndrome (AIDS)~* History of coexistent advanced malignancy~* History of coexistent severe cardiovascular disease~* History of coexistent severe renal disease~* History of current excessive or recent (within 6 months) alcohol use~* Any condition that, in the opinion of the investigators, would interfere with the patient's ability to complete the study safely or successfully~* History of thrombolytic events. Combination use with corticosteroids increases risk of deep vein thrombosis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 72 Years
- Healthy Volunteers: f

Study Arms:
- Thalidomide (Type: EXPERIMENTAL): Participants will be treated with Thalidomide, starting at a dose of 100 mg per day, increasing the dose by 100 mg every 14 days to a maximum of 400 mg per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Blood Flow Characteristics in Glaucoma Using Optical Coherence Tomography Angiography (OCT-A).

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of open angle glaucoma (OAG) including pseudo-exfoliative and pigmentary glaucoma.~* Documented glaucomatous visual field damage (in the previous 12 months with mean defect (MD) \> 2.0 dB)~* Structural and/or functional glaucomatous damage~* Have given written informed consent, prior to any investigational procedures~Exclusion Criteria:~* Patients with allergy to corneal anesthetic~* Patients not able to understand the character and individual consequences of the investigation~* Participation in other clinical research within the last 4 weeks~* Other diseases that may cause visual field loss or optic disc abnormalities~* Refractive error of \> +3.00D or \< -7.00D

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Longitudinal arm (Type: None): Evaluate optic nerve head blood flow using the new OCT-A software in surgically and medically treated glaucoma patients and in different types of glaucoma
- 24-h Intraocular pressure (IOP) arm (Type: None): Evaluate the correlation between circadian IOP changes and optic nerve head blood flow using the new OCT-A software
- Surgery arm (Type: None): Evaluate blood flow using the new OCT-A software in surgically treated glaucoma patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues